Weilin Song1, Ya Qu1, Xiaoyong Huang2. 1. Southwest Hospital, Southwest Eye Hospital, Army Medical University, Chongqing, People's Republic of China. 2. Southwest Hospital, Southwest Eye Hospital, Army Medical University, Chongqing, People's Republic of China. huangxiaoyongeye@163.com.
Abstract
PURPOSE: To evaluate the efficiency of plasma exchange (PE) add-on on optic neuritis (ON) in neuromyelitis optica spectrum disorders (NMOSD). METHODS: Our ambispective, nonrandomized study was performed in Southwest Hospital, Southwest Eye Hospital, Army Medical University. We studied 31 consecutive NMOSD patients characterized by ON and hospitalized from September 2015 to May 2018. Their clinical features were assessed, and efficiency of PE add-on treatment in ON of NMOSD was evaluated. Correlation was assessed between the effect of steroid pulse therapy (SPT) and the number of ON episodes in NMOSD. RESULTS: All 31 NMOSD patients accepted SPT; 15 patients of them accepted SPT and PE add-on. In these 15 patients, after PE add-on treatment, the patients' visual acuity was further significantly improved (P = 0.000, N = 23), including 3 no light perception (NLP) patients. After the treatment, the visual function recovered quickly in the first 2 months and then gradually slowed down; the visual function remained stable about 6 months later. The correlation coefficient between visual acuity improvement of SPT and the number of ON episodes was - 0.311 (P = 0.030, N = 49). CONCLUSION: One clinical feature of NMOSD can be repeated vision impairment. In NMOSD patients characterized by ON, efficacy of SPT is limited as the number of episodes increased, and PE add-on is more effective. Even though the visual acuity of NMOSD patients decreases to NLP during episodes, there is still a chance to restore vision by PE add-on treatment.
PURPOSE: To evaluate the efficiency of plasma exchange (PE) add-on on optic neuritis (ON) in neuromyelitis optica spectrum disorders (NMOSD). METHODS: Our ambispective, nonrandomized study was performed in Southwest Hospital, Southwest Eye Hospital, Army Medical University. We studied 31 consecutive NMOSD patients characterized by ON and hospitalized from September 2015 to May 2018. Their clinical features were assessed, and efficiency of PE add-on treatment in ON of NMOSD was evaluated. Correlation was assessed between the effect of steroid pulse therapy (SPT) and the number of ON episodes in NMOSD. RESULTS: All 31 NMOSD patients accepted SPT; 15 patients of them accepted SPT and PE add-on. In these 15 patients, after PE add-on treatment, the patients' visual acuity was further significantly improved (P = 0.000, N = 23), including 3 no light perception (NLP) patients. After the treatment, the visual function recovered quickly in the first 2 months and then gradually slowed down; the visual function remained stable about 6 months later. The correlation coefficient between visual acuity improvement of SPT and the number of ON episodes was - 0.311 (P = 0.030, N = 49). CONCLUSION: One clinical feature of NMOSD can be repeated vision impairment. In NMOSD patients characterized by ON, efficacy of SPT is limited as the number of episodes increased, and PE add-on is more effective. Even though the visual acuity of NMOSD patients decreases to NLP during episodes, there is still a chance to restore vision by PE add-on treatment.
Authors: Chidi Okafor; David M Ward; Michele H Mokrzycki; Robert Weinstein; Pamela Clark; Rasheed A Balogun Journal: J Clin Apher Date: 2010 Impact factor: 2.821
Authors: J Sellner; M Boggild; M Clanet; R Q Hintzen; Z Illes; X Montalban; R A Du Pasquier; C H Polman; P S Sorensen; B Hemmer Journal: Eur J Neurol Date: 2010-06-07 Impact factor: 6.089
Authors: Julien Ratelade; Nithi Asavapanumas; Alanna M Ritchie; Scott Wemlinger; Jeffrey L Bennett; A S Verkman Journal: Acta Neuropathol Date: 2013-08-31 Impact factor: 17.088
Authors: Jeffrey L Bennett; Chiwah Lam; Sudhakar Reddy Kalluri; Philippe Saikali; Katherine Bautista; Cecily Dupree; Magdalena Glogowska; David Case; Jack P Antel; Gregory P Owens; Don Gilden; Stefan Nessler; Christine Stadelmann; Bernhard Hemmer Journal: Ann Neurol Date: 2009-11 Impact factor: 10.422
Authors: Claudia F Lucchinetti; Raul N Mandler; Dorian McGavern; Wolfgang Bruck; Gerald Gleich; Richard M Ransohoff; Corinna Trebst; Brian Weinshenker; Dean Wingerchuk; Joseph E Parisi; Hans Lassmann Journal: Brain Date: 2002-07 Impact factor: 13.501
Authors: Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker Journal: Neurology Date: 2015-06-19 Impact factor: 9.910